NewAmsterdam Pharma (NAMS)

• Market cap: $3.78B
• 1 day: -2.82%
• 5 days: -9.69%
• 1 month: 5.72%
• 3 months: -4.88%
• 6 months: 1.63%
• Year to date: -8.1%
• 1 year: 53.9%
• 5 years: 212.56%
• 10 years: 212.56%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Employees: 100